Bosentan CAS: 147536-97-8
MF: C27H29N5O6S
MW: 551.61
A mixed endothelin receptor antagonist.

Bosentan (CAS 147536-97-8)

Bosentan | CAS 147536-97-8 is rated 5.0 out of 5 by 1.
  • y_2020, m_5, d_27, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_210957, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 109ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Actelion
Application: Bosentan is a mixed endothelin receptor antagonist
CAS Number: 147536-97-8
Purity: ≥98%
Molecular Weight: 551.61
Molecular Formula: C27H29N5O6S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Bosentan is a mixed endothelin receptor antagonist which is used as a vasodilator. Bosentan is an inhibitor of ETAR and ETBR.


References

Clozel, M., et al.: J. Pharmacol. Exp. Ther., 270, 228 (1994), Gutsch, G., et al.: Cardiovasc. Drugs Ther., 10, 717 (1996), Weber, C., et al.: Clin Pharmacol. Ther., 60, 124 (1996), Krum, H., et al.: N. Engl. J. Med., 338, 784 (1998)

Physical State :
Solid
Storage :
Store at -20° C
Melting Point :
107-110° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
104865
SMILES :
CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Bosentan (CAS 147536-97-8) Product Citations

See how others have used Bosentan (CAS 147536-97-8). Click on the entry to view the PubMed entry .

Citations 1 to 3 of 3 total

PMID: # 27083147  Eakins, J. et al. 2016. Toxicol In Vitro. 34: 161-170.

PMID: # 25573237  Zhang, L. et al. 2015. International journal of molecular medicine. 35: 784-90.

PMID: # 24910239  Penner, N. et al. 2014. Drug Metab Lett. 8: 36-42.

Citations 1 to 3 of 3 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 107ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Serafim et al Serafim et al. (PubMed ID 26246053) found that the mixed endothelin receptor antagonist, Bosentan, inhibited superoxide anion-induced pain, inflammation, cytokine production, and oxidative stress. -SCBT Publication Review
Date published: 2015-03-01
  • y_2020, m_5, d_27, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_210957, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.